CNS5:Ganglioglioma - Revision history

Bailey.Glen at 17:35, 3 July 2025

2025-07-03T17:35:38Z

← Older revision		Revision as of 12:35, 3 July 2025
Line 30:		Line 30:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:56, 25 May 2025

2025-05-25T21:56:00Z

← Older revision		Revision as of 16:56, 25 May 2025
Line 220:		Line 220:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 459:		Line 459:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 493:		Line 493:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:41, 25 May 2025

2025-05-25T20:41:29Z

← Older revision		Revision as of 15:41, 25 May 2025
Line 45:		Line 45:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 19:40, 25 May 2025

2025-05-25T19:40:10Z

← Older revision		Revision as of 14:40, 25 May 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Ganglioglioma}}		{{DISPLAYTITLE:Ganglioglioma}}

	[[CNS5:Table_of_Contents\|Central Nervous System Tumours(WHO Classification, 5th ed.)]]		[[CNS5:Table_of_Contents\|Central Nervous System Tumours (WHO Classification, 5th ed.)]]

	{{Under Construction}}		{{Under Construction}}

Jennelleh at 01:27, 28 March 2025

2025-03-28T01:27:28Z

@@ Line 28: / Line 28: @@
 |Subtype(s)
 |Ganglioglioma
 |}

Jennelleh at 21:21, 27 March 2025

2025-03-27T21:21:49Z

Jennelleh at 21:21, 27 March 2025

2025-03-27T21:21:33Z

Show changes

Jennelleh at 21:14, 27 March 2025

2025-03-27T21:14:19Z

← Older revision		Revision as of 16:14, 27 March 2025
Line 161:		Line 161:


			'''Add content below into table above''' -
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Chromosomal Rearrangement'''		\|'''Chromosomal Rearrangement'''
Line 312:		Line 313:
	\|		\|
	\|}		\|}
			'''Add content below into table above''' -
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Chr # '''		\|'''Chr # '''
Line 579:		Line 580:


			'''Add content below into table above''' -
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Gene; Genetic Alteration'''		\|'''Gene; Genetic Alteration'''
Line 654:		Line 656:
	<br />		<br />
	\|}		\|}


	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 697:		Line 698:
	Inactivating germline mutations or deletions of ''NF1'', as occurs in neurofibromatosis type 1, can be associated with a minor proportion of gangliogliomas<ref name=":6" /><ref>{{Cite journal\|last=Rodriguez\|first=Fausto J.\|last2=Perry\|first2=Arie\|last3=Gutmann\|first3=David H.\|last4=O'Neill\|first4=Brian Patrick\|last5=Leonard\|first5=Jeffrey\|last6=Bryant\|first6=Sandra\|last7=Giannini\|first7=Caterina\|date=2008-03\|title=Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients\|url=https://pubmed.ncbi.nlm.nih.gov/18344915\|journal=Journal of Neuropathology and Experimental Neurology\|volume=67\|issue=3\|pages=240–249\|doi=10.1097/NEN.0b013e318165eb75\|issn=0022-3069\|pmc=3417064\|pmid=18344915}}</ref>		Inactivating germline mutations or deletions of ''NF1'', as occurs in neurofibromatosis type 1, can be associated with a minor proportion of gangliogliomas<ref name=":6" /><ref>{{Cite journal\|last=Rodriguez\|first=Fausto J.\|last2=Perry\|first2=Arie\|last3=Gutmann\|first3=David H.\|last4=O'Neill\|first4=Brian Patrick\|last5=Leonard\|first5=Jeffrey\|last6=Bryant\|first6=Sandra\|last7=Giannini\|first7=Caterina\|date=2008-03\|title=Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients\|url=https://pubmed.ncbi.nlm.nih.gov/18344915\|journal=Journal of Neuropathology and Experimental Neurology\|volume=67\|issue=3\|pages=240–249\|doi=10.1097/NEN.0b013e318165eb75\|issn=0022-3069\|pmc=3417064\|pmid=18344915}}</ref>

	== Additional Information~~[edit \| edit source]~~ ==		==Additional Information==
	~~Put your text here~~		This disease is <u>defined/characterized</u> as detailed below:


			The <u>epidemiology/prevalence</u> of this disease is detailed below:


			The <u>clinical features</u> of this disease are detailed below:

			Signs and symptoms -

			Laboratory findings -

			The <u>sites of involvement</u> of this disease are detailed below:


			The <u>morphologic features</u> of this disease are detailed below:


			The <u>immunophenotype</u> of this disease is detailed below:

			Positive (universal) -

			Positive (majority) -

			Negative (universal) -

			Negative (subset) -

	==Links==		==Links==
Line 708:		Line 735:
	<br />		<br />

	== Notes[edit \| edit source] ==		==Notes[edit \| edit source]==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''Associate Editor'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''Associate Editor'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

Bailey.Glen: rebuilding template

2025-03-27T14:56:14Z

rebuilding template

← Older revision		Revision as of 09:56, 27 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Ganglioglioma}}		{{DISPLAYTITLE:Ganglioglioma}}

	[[CNS5:Table_of_Contents\|Central Nervous System Tumours(WHO Classification, 5th ed.)]]		[[CNS5:Table_of_Contents\|Central Nervous System Tumours(WHO Classification, 5th ed.)]]

Line 158:		Line 159:
	\|		\|
	\|}		\|}



Line 257:		Line 257:
	<br />		<br />
	\|}		\|}



Line 578:		Line 577:
	\|		\|
	\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.		\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.



Line 658:		Line 656:


			==Epigenomic Alterations==
	==~~Epigenomics (Methylation)~~==

	Methylation profiling can be used in the diagnosis of ganglioglioma, however low tumour cellularity can impact on feasibility in the diagnostic setting<ref name=":0" />.		Methylation profiling can be used in the diagnosis of ganglioglioma, however low tumour cellularity can impact on feasibility in the diagnostic setting<ref name=":0" />.

	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==
	~~Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Please include references throughout the table. Do not delete the table.)''</span>~~
	~~{\| class="wikitable sortable"~~
	\|-
	~~!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome~~
	\|-
	~~\|<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations~~
	~~\|<span class="blue-text">EXAMPLE:</span> MAPK signaling~~
	~~\|<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation~~
	\|-
	~~\|<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations~~
	~~\|<span class="blue-text">EXAMPLE:</span> Cell cycle regulation~~
	~~\|<span class="blue-text">EXAMPLE:</span> Unregulated cell division~~
	\|-
	~~\|<span class="blue-text">EXAMPLE:</span> ''KMT2C'' and ''ARID1A''; Inactivating mutations~~
	~~\|<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling~~
	~~\|<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program~~
	\|-
	\|
	\|
	\|
	\|}




	90% of gangliogliomas harbor genetic alterations activating the MAPK signaling pathway, with non-MAPK signaling seen in 10% of cases (e.g. ''ABL2::GAB2'' gene fusion)<ref name=":6" />.		90% of gangliogliomas harbor genetic alterations activating the MAPK signaling pathway, with non-MAPK signaling seen in 10% of cases (e.g. ''ABL2::GAB2'' gene fusion)<ref name=":6" />.
	{\| class="wikitable"		{\| class="wikitable"
Line 715:		Line 687:
	\|Increase cell growth and proliferation		\|Increase cell growth and proliferation
	\|}		\|}
			==Genetic Diagnostic Testing Methods==


	==Diagnostic Testing Methods==

	*Chromosome microarray		*Chromosome microarray
Line 726:		Line 695:
	==Familial Forms==		==Familial Forms==

	Inactivating germline mutations or deletions of ''NF1'', as occurs in neurofibromatosis type 1, can be associated with a minor proportion of gangliogliomas<ref name=":6" /><ref>{{Cite journal\|last=Rodriguez\|first=Fausto J.\|last2=Perry\|first2=Arie\|last3=Gutmann\|first3=David H.\|last4=O'Neill\|first4=Brian Patrick\|last5=Leonard\|first5=Jeffrey\|last6=Bryant\|first6=Sandra\|last7=Giannini\|first7=Caterina\|date=2008-03\|title=Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients\|url=https://pubmed.ncbi.nlm.nih.gov/18344915\|journal=Journal of Neuropathology and Experimental Neurology\|volume=67\|issue=3\|pages=240–249\|doi=10.1097/NEN.0b013e318165eb75\|issn=0022-3069\|pmc=3417064\|pmid=18344915}}</ref>		Inactivating germline mutations or deletions of ''NF1'', as occurs in neurofibromatosis type 1, can be associated with a minor proportion of gangliogliomas<ref name=":6" /><ref>{{Cite journal\|last=Rodriguez\|first=Fausto J.\|last2=Perry\|first2=Arie\|last3=Gutmann\|first3=David H.\|last4=O'Neill\|first4=Brian Patrick\|last5=Leonard\|first5=Jeffrey\|last6=Bryant\|first6=Sandra\|last7=Giannini\|first7=Caterina\|date=2008-03\|title=Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients\|url=https://pubmed.ncbi.nlm.nih.gov/18344915\|journal=Journal of Neuropathology and Experimental Neurology\|volume=67\|issue=3\|pages=240–249\|doi=10.1097/NEN.0b013e318165eb75\|issn=0022-3069\|pmc=3417064\|pmid=18344915}}</ref>

			== Additional Information[edit \| edit source] ==
			Put your text here

	==Links==		==Links==
Line 734:		Line 706:
	==References==		==References==
	<references />		<references />
			<br />

			== Notes[edit \| edit source] ==
			<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''Associate Editor'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

	<nowiki>*</nowiki>''Citation of this Page'': “Ganglioglioma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/CNS5:Ganglioglioma</nowiki>.		<nowiki>*</nowiki>''Citation of this Page'': “Ganglioglioma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/CNS5:Ganglioglioma</nowiki>.
	[[Category:CNS5]][[Category:DISEASE]][[Category:Diseases G]]		[[Category:CNS5]]
			[[Category:DISEASE]]
			[[Category:Diseases G]]

Bailey.Glen: /* Genomic Gain/Loss/LOH */

2025-03-27T14:53:07Z

Genomic Gain/Loss/LOH

Show changes

← Older revision		Revision as of 16:21, 27 March 2025
Line 8:		Line 8:
	==Primary Author(s)*==		==Primary Author(s)*==
	Dr Leila Moayed Alaei, Royal Prince Alfred Hospital		Dr Leila Moayed Alaei, Royal Prince Alfred Hospital


	==WHO Classification of Disease==		==WHO Classification of Disease==

Line 634:		Line 632:
	This disease is <u>defined/characterized</u> as detailed below:		This disease is <u>defined/characterized</u> as detailed below:

	* This is a distinct entity in the World Health Organization (WHO) classification system within the section of Gliomas, Glioneuronal and neuronal tumours. This is a well-differentiated glioneuronal tumour with low proliferative activity, comprised of mixed neoplastic neuronal and glial cell components. It is molecularly characterized by genomic aberrations causing MAPK pathway activation (CNS WHO grade 1)<ref name=":0" />.		*This is a distinct entity in the World Health Organization (WHO) classification system within the section of Gliomas, Glioneuronal and neuronal tumours. This is a well-differentiated glioneuronal tumour with low proliferative activity, comprised of mixed neoplastic neuronal and glial cell components. It is molecularly characterized by genomic aberrations causing MAPK pathway activation (CNS WHO grade 1)<ref name=":0" />.

	The <u>epidemiology/prevalence</u> of this disease is detailed below:		The <u>epidemiology/prevalence</u> of this disease is detailed below:

	* Gangliogliomas are generally tumours of adolescent/young adults with a median age of 12 years at the time of diagnosis. However, the tumour has been reported in wider range of age from 0 to 70 years of age<ref>{{Cite journal\|last=Lang\|first=Shih-Shan\|last2=Beslow\|first2=Lauren A.\|last3=Gabel\|first3=Brandon\|last4=Judkins\|first4=Alex R.\|last5=Fisher\|first5=Michael J.\|last6=Sutton\|first6=Leslie N.\|last7=Storm\|first7=Phillip B.\|last8=Heuer\|first8=Gregory G.\|date=2012-07\|title=Surgical treatment of brain tumors in infants younger than six months of age and review of the literature\|url=https://pubmed.ncbi.nlm.nih.gov/22120270\|journal=World Neurosurgery\|volume=78\|issue=1-2\|pages=137–144\|doi=10.1016/j.wneu.2011.09.012\|issn=1878-8769\|pmc=3292637\|pmid=22120270}}</ref><ref name=":3">{{Cite journal\|last=Blumcke\|first=Ingmar\|last2=Spreafico\|first2=Roberto\|last3=Haaker\|first3=Gerrit\|last4=Coras\|first4=Roland\|last5=Kobow\|first5=Katja\|last6=Bien\|first6=Christian G.\|last7=Pfäfflin\|first7=Margarete\|last8=Elger\|first8=Christian\|last9=Widman\|first9=Guido\|date=2017-10-26\|title=Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery\|url=https://pubmed.ncbi.nlm.nih.gov/29069555\|journal=The New England Journal of Medicine\|volume=377\|issue=17\|pages=1648–1656\|doi=10.1056/NEJMoa1703784\|issn=1533-4406\|pmid=29069555}}</ref>. The tumour is more prevalent in male patients (59.8%) than in female patients (40.2%)<ref>{{Cite journal\|last=Dudley\|first=Roy W. R.\|last2=Torok\|first2=Michelle R.\|last3=Gallegos\|first3=Danielle R.\|last4=Mulcahy-Levy\|first4=Jean M.\|last5=Hoffman\|first5=Lindsey M.\|last6=Liu\|first6=Arthur K.\|last7=Handler\|first7=Michael H.\|last8=Hankinson\|first8=Todd C.\|date=2015-03\|title=Pediatric low-grade ganglioglioma: epidemiology, treatments, and outcome analysis on 348 children from the surveillance, epidemiology, and end results database\|url=https://pubmed.ncbi.nlm.nih.gov/25603107\|journal=Neurosurgery\|volume=76\|issue=3\|pages=313–319; discussion 319; quiz 319–320\|doi=10.1227/NEU.0000000000000619\|issn=1524-4040\|pmc=4333003\|pmid=25603107}}</ref>.		*Gangliogliomas are generally tumours of adolescent/young adults with a median age of 12 years at the time of diagnosis. However, the tumour has been reported in wider range of age from 0 to 70 years of age<ref>{{Cite journal\|last=Lang\|first=Shih-Shan\|last2=Beslow\|first2=Lauren A.\|last3=Gabel\|first3=Brandon\|last4=Judkins\|first4=Alex R.\|last5=Fisher\|first5=Michael J.\|last6=Sutton\|first6=Leslie N.\|last7=Storm\|first7=Phillip B.\|last8=Heuer\|first8=Gregory G.\|date=2012-07\|title=Surgical treatment of brain tumors in infants younger than six months of age and review of the literature\|url=https://pubmed.ncbi.nlm.nih.gov/22120270\|journal=World Neurosurgery\|volume=78\|issue=1-2\|pages=137–144\|doi=10.1016/j.wneu.2011.09.012\|issn=1878-8769\|pmc=3292637\|pmid=22120270}}</ref><ref name=":3">{{Cite journal\|last=Blumcke\|first=Ingmar\|last2=Spreafico\|first2=Roberto\|last3=Haaker\|first3=Gerrit\|last4=Coras\|first4=Roland\|last5=Kobow\|first5=Katja\|last6=Bien\|first6=Christian G.\|last7=Pfäfflin\|first7=Margarete\|last8=Elger\|first8=Christian\|last9=Widman\|first9=Guido\|date=2017-10-26\|title=Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery\|url=https://pubmed.ncbi.nlm.nih.gov/29069555\|journal=The New England Journal of Medicine\|volume=377\|issue=17\|pages=1648–1656\|doi=10.1056/NEJMoa1703784\|issn=1533-4406\|pmid=29069555}}</ref>. The tumour is more prevalent in male patients (59.8%) than in female patients (40.2%)<ref>{{Cite journal\|last=Dudley\|first=Roy W. R.\|last2=Torok\|first2=Michelle R.\|last3=Gallegos\|first3=Danielle R.\|last4=Mulcahy-Levy\|first4=Jean M.\|last5=Hoffman\|first5=Lindsey M.\|last6=Liu\|first6=Arthur K.\|last7=Handler\|first7=Michael H.\|last8=Hankinson\|first8=Todd C.\|date=2015-03\|title=Pediatric low-grade ganglioglioma: epidemiology, treatments, and outcome analysis on 348 children from the surveillance, epidemiology, and end results database\|url=https://pubmed.ncbi.nlm.nih.gov/25603107\|journal=Neurosurgery\|volume=76\|issue=3\|pages=313–319; discussion 319; quiz 319–320\|doi=10.1227/NEU.0000000000000619\|issn=1524-4040\|pmc=4333003\|pmid=25603107}}</ref>.

	The <u>clinical features</u> of this disease are detailed below:		The <u>clinical features</u> of this disease are detailed below:

	* The clinical features are dependent on the tumour location and size. If located in the cerebrum, the most common presentation is with focal seizures<ref name=":0" /><ref name=":1">{{Cite journal\|last=Prayson\|first=R. A.\|last2=Khajavi\|first2=K.\|last3=Comair\|first3=Y. G.\|date=1995-07\|title=Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors\|url=https://pubmed.ncbi.nlm.nih.gov/7541447\|journal=Journal of Neuropathology and Experimental Neurology\|volume=54\|issue=4\|pages=513–520\|doi=10.1097/00005072-199507000-00005\|issn=0022-3069\|pmid=7541447}}</ref>, with up to 23.6% of surgical epilepsy specimens harbouring gangliogliomas<ref>{{Cite journal\|last=Blumcke\|first=Ingmar\|last2=Spreafico\|first2=Roberto\|last3=Haaker\|first3=Gerrit\|last4=Coras\|first4=Roland\|last5=Kobow\|first5=Katja\|last6=Bien\|first6=Christian G.\|last7=Pfäfflin\|first7=Margarete\|last8=Elger\|first8=Christian\|last9=Widman\|first9=Guido\|date=2017-10-26\|title=Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery\|url=https://pubmed.ncbi.nlm.nih.gov/29069555\|journal=The New England Journal of Medicine\|volume=377\|issue=17\|pages=1648–1656\|doi=10.1056/NEJMoa1703784\|issn=1533-4406\|pmid=29069555}}</ref>. The mean duration of symptoms prior to diagnosis is also dependent on location. For tumours located in the cerebrum, the duration of symptoms prior to diagnosis ranges between 5 and 10 years, whereas in the brainstem and spinal cord, the mean duration of symptoms pre-diagnosis ranges between 1.25 years and 1.4 years, respectively<ref name=":1" /><ref name=":4">{{Cite journal\|last=Lang\|first=F. F.\|last2=Epstein\|first2=F. J.\|last3=Ransohoff\|first3=J.\|last4=Allen\|first4=J. C.\|last5=Wisoff\|first5=J.\|last6=Abbott\|first6=I. R.\|last7=Miller\|first7=D. C.\|date=1993-12\|title=Central nervous system gangliogliomas. Part 2: Clinical outcome\|url=https://pubmed.ncbi.nlm.nih.gov/8246055\|journal=Journal of Neurosurgery\|volume=79\|issue=6\|pages=867–873\|doi=10.3171/jns.1993.79.6.0867\|issn=0022-3085\|pmid=8246055}}</ref>.		*The clinical features are dependent on the tumour location and size. If located in the cerebrum, the most common presentation is with focal seizures<ref name=":0" /><ref name=":1">{{Cite journal\|last=Prayson\|first=R. A.\|last2=Khajavi\|first2=K.\|last3=Comair\|first3=Y. G.\|date=1995-07\|title=Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors\|url=https://pubmed.ncbi.nlm.nih.gov/7541447\|journal=Journal of Neuropathology and Experimental Neurology\|volume=54\|issue=4\|pages=513–520\|doi=10.1097/00005072-199507000-00005\|issn=0022-3069\|pmid=7541447}}</ref>, with up to 23.6% of surgical epilepsy specimens harbouring gangliogliomas<ref>{{Cite journal\|last=Blumcke\|first=Ingmar\|last2=Spreafico\|first2=Roberto\|last3=Haaker\|first3=Gerrit\|last4=Coras\|first4=Roland\|last5=Kobow\|first5=Katja\|last6=Bien\|first6=Christian G.\|last7=Pfäfflin\|first7=Margarete\|last8=Elger\|first8=Christian\|last9=Widman\|first9=Guido\|date=2017-10-26\|title=Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery\|url=https://pubmed.ncbi.nlm.nih.gov/29069555\|journal=The New England Journal of Medicine\|volume=377\|issue=17\|pages=1648–1656\|doi=10.1056/NEJMoa1703784\|issn=1533-4406\|pmid=29069555}}</ref>. The mean duration of symptoms prior to diagnosis is also dependent on location. For tumours located in the cerebrum, the duration of symptoms prior to diagnosis ranges between 5 and 10 years, whereas in the brainstem and spinal cord, the mean duration of symptoms pre-diagnosis ranges between 1.25 years and 1.4 years, respectively<ref name=":1" /><ref name=":4">{{Cite journal\|last=Lang\|first=F. F.\|last2=Epstein\|first2=F. J.\|last3=Ransohoff\|first3=J.\|last4=Allen\|first4=J. C.\|last5=Wisoff\|first5=J.\|last6=Abbott\|first6=I. R.\|last7=Miller\|first7=D. C.\|date=1993-12\|title=Central nervous system gangliogliomas. Part 2: Clinical outcome\|url=https://pubmed.ncbi.nlm.nih.gov/8246055\|journal=Journal of Neurosurgery\|volume=79\|issue=6\|pages=867–873\|doi=10.3171/jns.1993.79.6.0867\|issn=0022-3085\|pmid=8246055}}</ref>.
	* The archetypal radiological features are of a circumscribed, solid/cystic mass, although varied appearances are the norm, ranging from presentation as a small cyst to a solid mass<ref name=":2">{{Cite journal\|last=Zhang\|first=D.\|last2=Henning\|first2=T. D.\|last3=Zou\|first3=L.-G.\|last4=Hu\|first4=L.-B.\|last5=Wen\|first5=L.\|last6=Feng\|first6=X.-Y.\|last7=Dai\|first7=S.-H.\|last8=Wang\|first8=W.-X.\|last9=Sun\|first9=Q.-R.\|date=2008-01\|title=Intracranial ganglioglioma: clinicopathological and MRI findings in 16 patients\|url=https://pubmed.ncbi.nlm.nih.gov/18068794\|journal=Clinical Radiology\|volume=63\|issue=1\|pages=80–91\|doi=10.1016/j.crad.2007.06.010\|issn=0009-9260\|pmid=18068794}}</ref>. Patterns of contrast enhancement can also vary, including enhancement of the cystic wall to a markedly enhanced nodule<ref name=":2" />.		*The archetypal radiological features are of a circumscribed, solid/cystic mass, although varied appearances are the norm, ranging from presentation as a small cyst to a solid mass<ref name=":2">{{Cite journal\|last=Zhang\|first=D.\|last2=Henning\|first2=T. D.\|last3=Zou\|first3=L.-G.\|last4=Hu\|first4=L.-B.\|last5=Wen\|first5=L.\|last6=Feng\|first6=X.-Y.\|last7=Dai\|first7=S.-H.\|last8=Wang\|first8=W.-X.\|last9=Sun\|first9=Q.-R.\|date=2008-01\|title=Intracranial ganglioglioma: clinicopathological and MRI findings in 16 patients\|url=https://pubmed.ncbi.nlm.nih.gov/18068794\|journal=Clinical Radiology\|volume=63\|issue=1\|pages=80–91\|doi=10.1016/j.crad.2007.06.010\|issn=0009-9260\|pmid=18068794}}</ref>. Patterns of contrast enhancement can also vary, including enhancement of the cystic wall to a markedly enhanced nodule<ref name=":2" />.
	* Signs and symptoms - Intracerebral ganglioglioma: Seizure; chronic temporal lobe epilepsy<ref name=":1" />; Brain stem ganglioglioma: blurry vision, loss of memory, syncope spells, cranial nerve deficits, headache, and gait instability<ref>{{Cite journal\|last=Mpairamidis\|first=Evriviadis\|last2=Alexiou\|first2=George A.\|last3=Stefanaki\|first3=Kalliopi\|last4=Sfakianos\|first4=George\|last5=Prodromou\|first5=Neofytos\|date=2008-12\|title=Brainstem ganglioglioma\|url=https://pubmed.ncbi.nlm.nih.gov/19073857\|journal=Journal of Child Neurology\|volume=23\|issue=12\|pages=1481–1483\|doi=10.1177/0883073808319316\|issn=1708-8283\|pmid=19073857}}</ref>; Spinal cord ganglioglioma: acute onset paraparesis<ref>{{Cite journal\|last=Cruz\|first=Thainá Zanon\|last2=Ferreira-Pinto\|first2=Pedro Henrique Costa\|last3=Brito\|first3=Ana Carolina Gonçalves\|last4=Ururahy\|first4=Leandro\|last5=Sanchez\|first5=Jefferson Trivino\|last6=Nigri\|first6=Flavio\|date=2021\|title=Ganglioglioma of the cervicothoracic spinal cord in a patient with neurofibromatosis type 1: A case report\|url=https://pubmed.ncbi.nlm.nih.gov/34345454\|journal=Surgical Neurology International\|volume=12\|pages=313\|doi=10.25259/SNI_192_2021\|issn=2229-5097\|pmc=8326088\|pmid=34345454}}</ref>		*Signs and symptoms - Intracerebral ganglioglioma: Seizure; chronic temporal lobe epilepsy<ref name=":1" />; Brain stem ganglioglioma: blurry vision, loss of memory, syncope spells, cranial nerve deficits, headache, and gait instability<ref>{{Cite journal\|last=Mpairamidis\|first=Evriviadis\|last2=Alexiou\|first2=George A.\|last3=Stefanaki\|first3=Kalliopi\|last4=Sfakianos\|first4=George\|last5=Prodromou\|first5=Neofytos\|date=2008-12\|title=Brainstem ganglioglioma\|url=https://pubmed.ncbi.nlm.nih.gov/19073857\|journal=Journal of Child Neurology\|volume=23\|issue=12\|pages=1481–1483\|doi=10.1177/0883073808319316\|issn=1708-8283\|pmid=19073857}}</ref>; Spinal cord ganglioglioma: acute onset paraparesis<ref>{{Cite journal\|last=Cruz\|first=Thainá Zanon\|last2=Ferreira-Pinto\|first2=Pedro Henrique Costa\|last3=Brito\|first3=Ana Carolina Gonçalves\|last4=Ururahy\|first4=Leandro\|last5=Sanchez\|first5=Jefferson Trivino\|last6=Nigri\|first6=Flavio\|date=2021\|title=Ganglioglioma of the cervicothoracic spinal cord in a patient with neurofibromatosis type 1: A case report\|url=https://pubmed.ncbi.nlm.nih.gov/34345454\|journal=Surgical Neurology International\|volume=12\|pages=313\|doi=10.25259/SNI_192_2021\|issn=2229-5097\|pmc=8326088\|pmid=34345454}}</ref>
	* Laboratory findings - Classic imaging features: T1 iso- to hypointense solid component, T2-hyperintense solid component with varied signal within the cystic component; nodule and cyst wall show variable contrast enhancement<ref name=":2" />		*Laboratory findings - Classic imaging features: T1 iso- to hypointense solid component, T2-hyperintense solid component with varied signal within the cystic component; nodule and cyst wall show variable contrast enhancement<ref name=":2" />

	The <u>sites of involvement</u> of this disease are detailed below:		The <u>sites of involvement</u> of this disease are detailed below:

	* Most common location: temporal lobes (>70%)<ref name=":1" /><ref name=":4" /><ref name=":5">{{Cite journal\|last=Wolf\|first=H. K.\|last2=Müller\|first2=M. B.\|last3=Spänle\|first3=M.\|last4=Zentner\|first4=J.\|last5=Schramm\|first5=J.\|last6=Wiestler\|first6=O. D.\|date=1994\|title=Ganglioglioma: a detailed histopathological and immunohistochemical analysis of 61 cases\|url=https://pubmed.ncbi.nlm.nih.gov/7985497\|journal=Acta Neuropathologica\|volume=88\|issue=2\|pages=166–173\|doi=10.1007/BF00294510\|issn=0001-6322\|pmid=7985497}}</ref>		*Most common location: temporal lobes (>70%)<ref name=":1" /><ref name=":4" /><ref name=":5">{{Cite journal\|last=Wolf\|first=H. K.\|last2=Müller\|first2=M. B.\|last3=Spänle\|first3=M.\|last4=Zentner\|first4=J.\|last5=Schramm\|first5=J.\|last6=Wiestler\|first6=O. D.\|date=1994\|title=Ganglioglioma: a detailed histopathological and immunohistochemical analysis of 61 cases\|url=https://pubmed.ncbi.nlm.nih.gov/7985497\|journal=Acta Neuropathologica\|volume=88\|issue=2\|pages=166–173\|doi=10.1007/BF00294510\|issn=0001-6322\|pmid=7985497}}</ref>
	* Other locations: cerebrum, brainstem, cerebellum, spinal cord, and optic nerves, lateral ventricle<ref name=":3" /><ref name=":1" /><ref name=":4" /><ref name=":5" />		*Other locations: cerebrum, brainstem, cerebellum, spinal cord, and optic nerves, lateral ventricle<ref name=":3" /><ref name=":1" /><ref name=":4" /><ref name=":5" />

	The <u>morphologic features</u> of this disease are detailed below:		The <u>morphologic features</u> of this disease are detailed below:

	* Ganglioglioma is a biphasic tumor composed of a neoplastic neuronal and a neoplastic glial component<ref name=":3" /><ref name=":5" />. The neoplastic neuronal component is comprised of dysmorphic ganglion cells showing cytomegaly, binucleation and perimembranous aggregation of Nissl substance. Disorganized cytoarchitecture is also observed, with clustering of neurons. The neoplastic glial component can resemble a diffuse glioma or pilocytic astrocytoma; the glial component harbors the proliferative component of the tumor, which can show infiltration on microscopy. Proliferative activity is usually low to absent. The two components can be intermingled or geographically distinct. Other pertinent histological features include Rosenthal fibres, eosinophilic granular bodies and perivascular lymphoid infiltration<ref name=":3" /><ref name=":5" />. An association with focal cortical dysplasia is a commonly reported finding<ref>{{Cite journal\|last=Blümcke\|first=Ingmar\|last2=Thom\|first2=Maria\|last3=Aronica\|first3=Eleonora\|last4=Armstrong\|first4=Dawna D.\|last5=Vinters\|first5=Harry V.\|last6=Palmini\|first6=Andre\|last7=Jacques\|first7=Thomas S.\|last8=Avanzini\|first8=Giuliano\|last9=Barkovich\|first9=A. James\|date=2011-01\|title=The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission\|url=https://pubmed.ncbi.nlm.nih.gov/21219302\|journal=Epilepsia\|volume=52\|issue=1\|pages=158–174\|doi=10.1111/j.1528-1167.2010.02777.x\|issn=1528-1167\|pmc=3058866\|pmid=21219302}}</ref>.		*Ganglioglioma is a biphasic tumor composed of a neoplastic neuronal and a neoplastic glial component<ref name=":3" /><ref name=":5" />. The neoplastic neuronal component is comprised of dysmorphic ganglion cells showing cytomegaly, binucleation and perimembranous aggregation of Nissl substance. Disorganized cytoarchitecture is also observed, with clustering of neurons. The neoplastic glial component can resemble a diffuse glioma or pilocytic astrocytoma; the glial component harbors the proliferative component of the tumor, which can show infiltration on microscopy. Proliferative activity is usually low to absent. The two components can be intermingled or geographically distinct. Other pertinent histological features include Rosenthal fibres, eosinophilic granular bodies and perivascular lymphoid infiltration<ref name=":3" /><ref name=":5" />. An association with focal cortical dysplasia is a commonly reported finding<ref>{{Cite journal\|last=Blümcke\|first=Ingmar\|last2=Thom\|first2=Maria\|last3=Aronica\|first3=Eleonora\|last4=Armstrong\|first4=Dawna D.\|last5=Vinters\|first5=Harry V.\|last6=Palmini\|first6=Andre\|last7=Jacques\|first7=Thomas S.\|last8=Avanzini\|first8=Giuliano\|last9=Barkovich\|first9=A. James\|date=2011-01\|title=The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission\|url=https://pubmed.ncbi.nlm.nih.gov/21219302\|journal=Epilepsia\|volume=52\|issue=1\|pages=158–174\|doi=10.1111/j.1528-1167.2010.02777.x\|issn=1528-1167\|pmc=3058866\|pmid=21219302}}</ref>.

	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below:

	* Positive (universal) - CD34 expressed in expressed in ramified tumor cells<ref>{{Cite journal\|last=Blümcke\|first=Ingmar\|last2=Wiestler\|first2=Otmar D.\|date=2002-07\|title=Gangliogliomas: an intriguing tumor entity associated with focal epilepsies\|url=https://pubmed.ncbi.nlm.nih.gov/12125736\|journal=Journal of Neuropathology and Experimental Neurology\|volume=61\|issue=7\|pages=575–584\|doi=10.1093/jnen/61.7.575\|issn=0022-3069\|pmid=12125736}}</ref>		*Positive (universal) - CD34 expressed in expressed in ramified tumor cells<ref>{{Cite journal\|last=Blümcke\|first=Ingmar\|last2=Wiestler\|first2=Otmar D.\|date=2002-07\|title=Gangliogliomas: an intriguing tumor entity associated with focal epilepsies\|url=https://pubmed.ncbi.nlm.nih.gov/12125736\|journal=Journal of Neuropathology and Experimental Neurology\|volume=61\|issue=7\|pages=575–584\|doi=10.1093/jnen/61.7.575\|issn=0022-3069\|pmid=12125736}}</ref>
	* Neoplastic neuronal component – MAP2, neurofilament, synaptophysin, chromogranin A (No definitive markers for neoplastic neuronal component; Typical profile: chromogranin A+, NeuN-, synaptophysin+, neurofilament+, MAP2+ (but MAP2 - in glial component)<ref name=":0" /><ref>{{Cite journal\|last=Blümcke\|first=Ingmar\|last2=Wiestler\|first2=Otmar D.\|date=2002-07\|title=Gangliogliomas: an intriguing tumor entity associated with focal epilepsies\|url=https://pubmed.ncbi.nlm.nih.gov/12125736\|journal=Journal of Neuropathology and Experimental Neurology\|volume=61\|issue=7\|pages=575–584\|doi=10.1093/jnen/61.7.575\|issn=0022-3069\|pmid=12125736}}</ref>)		*Neoplastic neuronal component – MAP2, neurofilament, synaptophysin, chromogranin A (No definitive markers for neoplastic neuronal component; Typical profile: chromogranin A+, NeuN-, synaptophysin+, neurofilament+, MAP2+ (but MAP2 - in glial component)<ref name=":0" /><ref>{{Cite journal\|last=Blümcke\|first=Ingmar\|last2=Wiestler\|first2=Otmar D.\|date=2002-07\|title=Gangliogliomas: an intriguing tumor entity associated with focal epilepsies\|url=https://pubmed.ncbi.nlm.nih.gov/12125736\|journal=Journal of Neuropathology and Experimental Neurology\|volume=61\|issue=7\|pages=575–584\|doi=10.1093/jnen/61.7.575\|issn=0022-3069\|pmid=12125736}}</ref>)
	* Neoplastic glial component – GFAP, OLIG2 (MAP2 -) (Ki-67 <5%<ref>{{Cite journal\|last=Prayson\|first=R. A.\|last2=Khajavi\|first2=K.\|last3=Comair\|first3=Y. G.\|date=1995-07\|title=Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors\|url=https://pubmed.ncbi.nlm.nih.gov/7541447\|journal=Journal of Neuropathology and Experimental Neurology\|volume=54\|issue=4\|pages=513–520\|doi=10.1097/00005072-199507000-00005\|issn=0022-3069\|pmid=7541447}}</ref>)		*Neoplastic glial component – GFAP, OLIG2 (MAP2 -) (Ki-67 <5%<ref>{{Cite journal\|last=Prayson\|first=R. A.\|last2=Khajavi\|first2=K.\|last3=Comair\|first3=Y. G.\|date=1995-07\|title=Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors\|url=https://pubmed.ncbi.nlm.nih.gov/7541447\|journal=Journal of Neuropathology and Experimental Neurology\|volume=54\|issue=4\|pages=513–520\|doi=10.1097/00005072-199507000-00005\|issn=0022-3069\|pmid=7541447}}</ref>)
	* Positive (subset) - BRAF VE1 (+ in BRAF-mutant gangliogliomas)<ref name=":0" />		*Positive (subset) - BRAF VE1 (+ in BRAF-mutant gangliogliomas)<ref name=":0" />
	* Negative (universal) - IDH1 R132H, ATRX (normal retained pattern of staining)<ref name=":0" />		*Negative (universal) - IDH1 R132H, ATRX (normal retained pattern of staining)<ref name=":0" />